TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06175273
Drug: Cyproheptadine
Normalized name: Cyproheptadine
DrugBank: Cyproheptadine (DB00434)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25mg/kg/d divided BID. May titrate by 4mg increments to a max of 12mg/day.
Study: NCT06175273
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5mg once a day (at night). May titrate by 2.5mg increments to max of 10mg/day
Study: NCT05661916
Drug: ALN-TTRSC04
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN-TTRSC04 will be administered by subcutaneous (SC) injection.
Study: NCT05052931
Drug: Nab-paclitaxel combined with oxaliplatin and S-1
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nab-paclitaxel 100mg/m\^2, D1, Q3W; oxaliplatin 85 mg/m\^2, D1, Q3W; S-1 60 mg/m\^2, D1-14, Q3W; Neoadjuvant chemotherapy 2 cycles, followed by surgery, continue to receive 6 cycles of adjuvant chemotherapy.
Study: NCT04805333
Drug: Artemisia annua 450mg
Normalized name: Artemisia annua pollen
DrugBank: Artemisia annua pollen (DB10582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
Study: NCT04805333
Drug: Artemisia annua 900mg
Normalized name: Artemisia annua pollen
DrugBank: Artemisia annua pollen (DB10582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
Study: NCT00811031
Drug: Taxotere
Normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m\^2 Day 1 of every 21-day cycle by vein for 4 cycles prior to surgery.
Study: NCT04805333
Drug: Artemisia annua 1350mg
Normalized name: Artemisia annua pollen
DrugBank: Artemisia annua pollen (DB10582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
Study: NCT00811031
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg twice a day by mouth.
Study: NCT06148649
Drug: HEC88473, Placebo, Dulaglutide
DrugBank: Dulaglutide (DB09045)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: T2DM subjects, receiving a weekly dose of HEC88473, placebo or dulaglutide.
Study: NCT05863325
Drug: Taxotere
Normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taxotere will be administered by intravenous (IV) injections on the first day of each cycle.
Study: NCT04805333
Drug: Artemisia annua 1800mg
Normalized name: Artemisia annua pollen
DrugBank: Artemisia annua pollen (DB10582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisia annua will be self-administered via a preparation of decaffeinated coffee.
Study: NCT04805333
Drug: Artemisia annua - recommended phase II dose
Normalized name: Artemisia annua pollen
DrugBank: Artemisia annua pollen (DB10582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisia annua will be self-administered via a preparation of decaffeinated coffee. The dose for this cohort will be based on analysis of previous cohorts.
Study: NCT05142423
Drug: AK109+AK104
Normalized name: Immunoglobulin g1, anti-(human vascular endothelial growth factor receptor 2) (human monoclonal ak109 .gamma.1-chain), disulfide with human monoclonal ak109 .kappa.-chain, dimer
DrugBank: Pulocimab (DB18938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: It includes dose escalation and dose expansion stage. 6-12 patients will be enrolled in dose escalation stage for safety and efficacy. Then select specific dose of AK104 and AK109. Expand for the further safety and efficacy study.
Study: NCT06087601
Drug: 0.9% Sodium chloride
Normalized name: LMD with 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: us-guided bilateral genicular nerves sham block with 0,5ml 0,9% normal saline
Study: NCT06087601
Drug: 95% ethanol
Normalized name: ALCOHOL 95 mL in 100 mL TOPICAL SOLUTION [95% Ethanol (190 Proof)]
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: us-guided bilateral genicular nerves neurolysis with 0,5ml 95% ethanol
Study: NCT04895358
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT04895358
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT04895358
Drug: dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT06006169
Drug: BL-B01D1
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BL-B01D1 was administered by intravenous infusion on D1, D8, or D1 in 3-week cycles.
Study: NCT06006169
Drug: SI-B003
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SI-B003 was administered intravenously every 3 weeks (Q3W).
Study: NCT05101928
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The comparator will be a prednisone taper which is currently the standard care for the uveitis types of focus.
Study: NCT05970354
Drug: EMLA Cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eutectic Mixture of Local Anesthetics (Lidocaine 2.5% and Prilocaine 2.5%)
Study: NCT06413108
Drug: TB31F
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: transmission-blocking monoclonal antibody TB31F
Study: NCT04776135
Drug: MT-1186
Normalized name: lipase
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension
Study: NCT05145283
Drug: Conestat alfa (Ruconest®)
Normalized name: conestat alfa
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: In the current study, participants will receive two intravenous injections of conestat alfa (immediately during the TAVI procedure and again 3h later) at a dose of 100 U/kg (first dose) and of 50 U/kg (subsequent dose), for patients less than 84 kg; two intravenous injections (immediately during the TAVI procedure and again 4h later) of conestat at a dose of 8400 U (4 vials, first dose) and of 4200 U (2 vials, subsequent dose) for patients of 84 kg body weight or greater. The chosen regimen including repeated administration should increase and maintain serum C1INH levels above twice the serum concentration for six to eight hours in the majority of patients. The timeframe of therapeutic concentrations will cover the period of the TAVI procedure itself and the immediate postprocedural period during which reperfusion and additional ischemic events related to global hypoperfusion may occur.
Study: NCT06533098
Drug: Nipocalimab
Normalized name: Nipocalimab
DrugBank: Nipocalimab (DB16257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nipocalimab will be administered intravenously.
Study: NCT06533098
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone will be administered orally.
Study: NCT04707300
Drug: Human T Lymphoid Progenitor (HTLP) injection
Normalized name: human cord blood hematopoietic progenitor cell
DrugBank: Human cord blood hematopoietic progenitor cell (DB11054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The HTLP cell suspension will be injected intravenously at the time of UCB HSCT on D0
Study: NCT05682222
Drug: EDP1815
Normalized name: EDP1815
DrugBank: EDP1815 (DB16486)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP1815 is an essentially non-viable, non-replicating pharmaceutical preparation of a single strain of Prevotella histicola, a naturally occurring human commensal microbe.
Study: NCT06565689
Drug: YK012
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: YK012 is a bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediated cytotoxicity of malignant B cells
Study: NCT04937452
Drug: Rotigotine 4Mg/24Hrs Patch
Normalized name: ROTIGOTINE 4MG/24HRS PATCH
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rotigotine 4 mg/24Hrs administration for 24 weeks
Study: NCT04937452
Drug: Rotigotine 6Mg/24Hrs Patch
Normalized name: ROTIGOTINE 6MG/24HRS PATCH
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rotigotine 6 mg/24Hrs administration for 24 weeks
Study: NCT06327724
Drug: Belimumab
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Start of new treatment due to active disease
Study: NCT00710216
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg/day
Study: NCT00710216
Drug: Telbivudine
Normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 600 mg/day
Study: NCT05248594
Drug: HEMLIBRA
Normalized name: Hemlibra
DrugBank: Emicizumab (DB13923)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Emicizumab (Hemlibra, also known as ACE910 and RO5534262) is a humanized monoclonal modified immunoglobulin G4 (IgG4) antibody with a bispecific antibody structure produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells.
Study: NCT06067698
Drug: Mesalamine and alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine 1000 mg every 8 hrs. + alpha-lipoic acid 600 mg once daily for 3 months
Study: NCT06650605
Drug: 123I-ATT001
Normalized name: 123I-
DrugBank: 123I-iodometomidate (DB13021)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 123I-ATT001
Study: NCT06207656
Drug: EBC
Normalized name: Nebcin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive the following per 28-day cycle:~* Encorafenib: 300 mg (4 × 75 mg oral capsule) daily (QD)~* Binimetinib: 45 mg (3 × 15 mg oral tablet) twice daily (BID)~* Cetuximab: 500 mg/m2 every 2 weeks as per standard institutional practice.
Study: NCT06022289
Drug: Pemigatinib
Normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pemigatinib will be treated according to the treatment plan of 2 weeks of administration/1 week of discontinuation, with oral administration of 1 capsule, 13.5mg, QD, and a cycle of 21 days. Meanwhile, the molecular testing results of the patient are analyzed and interpreted by the MTB team, and appropriate combination therapy(Pemigatinib+) strategies are proposed based on the patient's previous treatment history, physical condition, drug accessibility, and economic status.
Study: NCT06308107
Drug: IV Diazoxide
DrugBank: Diazoxide (DB01119)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 micromoles added to one liter of cardioplegia
Study: NCT04917406
Drug: Application of lidocaine together with dexamethasone
Normalized name: dexamethasone / lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 2% is applied on the positive pole while dexamethasone 4 mg/ml is applied on the negative pole. Through the use of current the drugs penetrate the fascia.
Study: NCT05012670
Drug: [14C]-Paxalisib Capsule
DrugBank: Paxalisib (DB15186)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive a single dose 15 mg (NMT 3.5 MBq), administered orally in the fasted state with with 240 mL water.
Study: NCT06014515
Drug: 18F-FDG
Normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.
Study: NCT04719156
Drug: Indocyanine green solution administered at 2.0mg/kg.
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosing of ICG to be administered at 2.0mg/kg, two hours prior to surgery.
Study: NCT05890729
Drug: XTMAB-16 or Placebo
Normalized name: XTMAB-16
DrugBank: XTMAB-16 (DB18380)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion
Study: NCT05911594
Drug: Solifenacin group
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in this group will receive medical treatment (Solifenacin 5 mg once or twice daily) without any second line of treatment
Study: NCT05911594
Drug: Intradetrusor BOTOX group
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Patients in this group will receive Intradetrusor BOTOX after failure of medical
Study: NCT05251779
Drug: Bergamot essential oils
Normalized name: BERGAMOT OIL
DrugBank: Bergamot oil (DB14335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group will be given Bergamot essential oils for inhalation.
Study: NCT05132803
Drug: HPV 16 TA-CIN
Normalized name: CIN-QUIN
DrugBank: TA-CIN (DB05809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No dose escalation or reduction
Study: NCT04855201
Drug: Bocidelpar
Normalized name: Bocidelpar
DrugBank: Bocidelpar (DB16906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT05874518
Drug: The treatment with letrozole tablets was started on the fifth day of the menstrual cycle
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole tablets were given at 2.5mg (Jiangsu Hengrui Pharmaceutical Co., Ltd., H19991001, 2.5mg per tablet), po (oral), qd, for 5-7 consecutive days. When the diameter of follicles reaches 18mm, Chorionic gonadotrophin is given at 5000u (Lizhu Group Lizhu Pharmaceutical Factory, Chinese medicine H44020668, 5000u per branch), with intramuscular injection, qd, to promote follicle discharge. Patients were also instructed to have sexual intercourse on the same day and on day 2.
Study: NCT05509192
Drug: MTPI
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients from both study groups will receive premedication in the usual fashion, typically 0-2 mg of IV midazolam at the discretion of the care team. Patients in both study groups will receive 1 mg/kg of lidocaine intravenously, followed by an opioid such as fentanyl (1-2 mcg/kg), prior to administration of induction drugs. Patients assigned to MTPI will then be given rocuronium (0.6mg/kg), followed by propofol intravenously as a single bolus within 10 seconds. A typical propofol bolus for induction ranges from 1-2mg/kg, depending on the patient's age, medical history, and co-morbidities. Propofol dosing will be at the discretion of the care team. Patients will count down from one hundred. Once apnea occurs, as indicated by a lack of respiratory effort, the eyes will be taped, and intubation with C-MAC (Karl Storz 8403ZX, Tuttlingen, Germany) is initiated.
Study: NCT06300307
Drug: ATX-01
Normalized name: ATX-01
DrugBank: ATX-01 (DB18141)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT05694026
Drug: Diquafosol tetrasodium
Normalized name: diquafosol tetrasodium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in dry eye signs and symptoms
Study: NCT05504876
Drug: Midazolam Syrup
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered Midazolam Syrup 5 mg orally once daily in fed state;
Study: NCT05312801
Drug: BAFF CAR-T
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous CAR-T cell therapy expressing the BAFF-ligand.
Study: NCT06323265
Drug: Adebrelimab + chemotherapy
Normalized name: menthol
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adebrelimab: 1200mg, d1, iv (30-60min), Q3W ,up to progressive disease or toxicity intolerable Chemotherapy: etoposide 100mg/m2，d1-3，iv；carboplatin AUC=5-6，d1，iv；or cisplatin 75mg/m2，d1，iv，Q3W，4 cycles；
Study: NCT06580444
Drug: Brexanolone
Normalized name: Brexanolone
DrugBank: Brexanolone (DB11859)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The participant will receive either a placebo, or 90, 60, or 30 mcg/kg/hr of Brexanolone over a 20-hour period intravenous infusion.
Study: NCT06579144
Drug: Efanesoctocog alfa
Normalized name: Efanesoctocog alfa
DrugBank: Efanesoctocog alfa (DB16662)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)
Study: NCT06580145
Drug: L-leucine
Normalized name: L-Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-leucine is an essential amino acid used to competitively inhibit kynurenine uptake into the brain via the large neutral amino acid transporter (LAT1).~The proposed dose for L-leucine is 4.31 g/day, administered orally.
Study: NCT06580145
Drug: L-lysine
Normalized name: L-Lysine
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-lysine monohydrochloride is also an essential amino acid. It serves as an active comparator to control for general effects on brain protein synthesis and enters the brain through separate cationic amino acid transporters.~The proposed dose for L-lysine is 6 g/day, administered orally
Study: NCT05021120
Drug: AK127
Normalized name: Abiraterone acetate
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will receive AK127 by intravenous administration
Study: NCT05021120
Drug: AK104
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After AK127 infusion, on the same day subjects will receive AK104 by intravenous administration
Study: NCT04633187
Drug: EDP-938
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP-938 800mg~Dose adjustments were made for subjects taking azole antifungals.
Study: NCT06449352
Drug: Netarsudil
Normalized name: NETARSUDIL
DrugBank: Netarsudil (DB13931)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: netarsudil 0.02%
Study: NCT06449352
Drug: Brimonidine
Normalized name: Brimonidine
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: brimonidine 0.1%
Study: NCT05481476
Drug: Surufatinib
Normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg, qd, po, 21 days for a cycle
Study: NCT05481476
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg, ivgtt, d1, 21 days for a cycle, up to 2 years
Study: NCT06023758
Drug: KN026
Normalized name: ANTI-HER2 BSAB KN026
DrugBank: Anbenitamab (DB18411)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KN026：30 mg/kg Q3W
Study: NCT06023758
Drug: KN046
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: KN046：5 mg/kg Q3W
Study: NCT04874311
Drug: Bintrafusp alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 2400 mg.
Study: NCT04608539
Drug: Ferric Derisomaltose
Normalized name: ferric derisomaltose
DrugBank: Ferric derisomaltose (DB15617)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose intravenous infusion, 20 mg/kg body weight, postoperative day 1
Study: NCT04608539
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral therapy, 100 mg twice daily, from postoperative day 4 until 4-week follow-up
Study: NCT06356155
Drug: Enfortumab vedotin
Normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.25 mg/kg IV
Study: NCT06356155
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg IV
Study: NCT05569174
Drug: secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AIN457 300 mg subcutaneously for 12 weeks
Study: NCT00101140
Drug: anti-thymocyte globulin
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00101140
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00101140
Drug: thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04764825
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dosage administered differ in regards to age and tolerance to opioids:~0.2 mg/kg: all patients \<65 years of age and all patients tolerant to opioids (defined as treatment with opioids (at least the last 7days) exceeding 60 oral morphine milligram equivalents daily.~0.15 mg/kg: Opioid naive patients \> 65 years of age.
Study: NCT04764825
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dosage administered differ in regards to age and tolerance to opioids:~0.2 mg/kg: all patients \<65 years of age and all patients tolerant to opioids (defined as treatment with opioids (at least the last 7days) exceeding 60 oral morphine milligram equivalents daily.~0.15 mg/kg: Opioid naive patients \> 65 years of age.
Study: NCT06102824
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800-1200mg/m2, IV, days 1, 8, q3w
Study: NCT06102824
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20-35mg/m2, IV, days 1 and 8, q3w
Study: NCT06102824
Drug: Eribulin
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1.4mg/m2, IV, days 1 and 8, q3w
Study: NCT06102824
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 6, IV, q3w or q4w OR Carboplatin AUC 2+Gemcitabine 1000mg/m2, IV, days 1 and 8, q3w OR Carboplatin AUC 2+Albumin-bound paclitaxel 125mg/m2, IV, days 1 and 8, q3w
Study: NCT06102824
Drug: Utidelone
Normalized name: Utidelone
DrugBank: Utidelone (DB17575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg/m2, IV, once per day on days 1-5, q3w
Study: NCT06102824
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5.4mg/kg, IV, q3w